The device is lighter than a Band-Aid and could be used as robot skin to track movement and health conditions. Photo via uh.edu

Imagine a wearable device so thin it's less noticeable and lighter than a Band-Aid but can track and record important health information. According to some University of Houston researchers, you might not need to imagine it at all.

A recent paper, which ran as the cover story in Science Advances, identified a wearable human-machine interface device that is so thin a wearer might not even notice it. Cunjiang Yu, a Bill D. Cook associate professor of Mechanical Engineering at the University of Houston, was the lead author for the paper.

"Everything is very thin, just a few microns thick," says Yu, who also is a principal investigator at the Texas Center for Superconductivity at UH, in a release. "You will not be able to feel it."

The device is reported in the paper to be made of a metal oxide semiconductor on a polymer base. It could be attached to a robotic hand or prosthetic, as well as other robotic devices, that can collect and report information to the wearer.

"What if when you shook hands with a robotic hand, it was able to instantly deduce physical condition?" Yu asks in the release.

The device could also be used to help make decisions in situations that are hazardous to humans, such as chemical spills.

Current devices on the market or being developed are much slower to respond and bulkier to wear, not to mention expensive to develop.

"We report an ultrathin, mechanically imperceptible, and stretchable (human-machine interface) HMI device, which is worn on human skin to capture multiple physical data and also on a robot to offer intelligent feedback, forming a closed-loop HMI," the researchers write in the paper. "The multifunctional soft stretchy HMI device is based on a one-step formed, sol-gel-on-polymer-processed indium zinc oxide semiconductor nanomembrane electronics."

The paper's co-authors, in addition to Yu, include first author Kyoseung Sim, Zhoulyu Rao, Faheem Ershad, Jianming Lei, Anish Thukral, and Jie Chen, who are all from UH; Zhanan Zou and Jianliang Xiao of the University of Colorado; and Qing-An Huang of Southeast University in Nanjing, China.


Soft Wearable Multifunctional Human-Machine Interfaces (HMIs)www.youtube.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.